In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Gritstone gets $21mm through Series C ahead of IPO

Executive Summary

Gritstone Oncology Inc. (cancer immunotherapies) raised $21mm through its Series C round, including a $10mm investment from new partner bluebird bio. The companies penned a deal potentially worth up to $1.2bn for Gritstone, through which the company will use its EDGE neoantigen platform to help bluebird discover and develop new cell therapies. The alliance and Series C round were announced in tandem with Gritstone's filing for its initial public offering.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies